Display options
Cite
Kaminetsky J, Jaffe JS, Swerdloff RS. Pharmacokinetic Profile of Subcutaneous Testosterone Enanthate Delivered via a Novel, Prefilled Single-Use Autoinjector: A Phase II Study. Sex Med. 2015;3(4):269-79doi: 10.1002/sm2.80.
Kaminetsky, J., Jaffe, J. S., & Swerdloff, R. S. (2015). Pharmacokinetic Profile of Subcutaneous Testosterone Enanthate Delivered via a Novel, Prefilled Single-Use Autoinjector: A Phase II Study. Sexual medicine, 3(4), 269-79. https://doi.org/10.1002/sm2.80
Kaminetsky, Jed, et al. "Pharmacokinetic Profile of Subcutaneous Testosterone Enanthate Delivered via a Novel, Prefilled Single-Use Autoinjector: A Phase II Study." Sexual medicine vol. 3,4 (2015): 269-79. doi: https://doi.org/10.1002/sm2.80
Kaminetsky J, Jaffe JS, Swerdloff RS. Pharmacokinetic Profile of Subcutaneous Testosterone Enanthate Delivered via a Novel, Prefilled Single-Use Autoinjector: A Phase II Study. Sex Med. 2015 Sep 17;3(4):269-79. doi: 10.1002/sm2.80. eCollection 2015 Dec. PMID: 26797061; PMCID: PMC4721027.
Copy Download .nbib Format: NLM
Share it on

Sex Med. 2015 Sep 17;3(4):269-79. doi: 10.1002/sm2.80. eCollection 2015 Dec.

Pharmacokinetic Profile of Subcutaneous Testosterone Enanthate Delivered via a Novel, Prefilled Single-Use Autoinjector: A Phase II Study.

Sexual medicine

Jed Kaminetsky, Jonathan S Jaffe, Ronald S Swerdloff

Affiliations

  1. Manhattan Medical Research University Urology New York NY USA.
  2. Antares Pharma, Inc. Ewing NJ USA.
  3. Endocrinology Los Angeles Biomedical Research Institute Harbor-University of California Medical Center Torrance CA USA.

PMID: 26797061 PMCID: PMC4721027 DOI: 10.1002/sm2.80

Abstract

INTRODUCTION: Hypogonadism is one of the most common male endocrine problems. Although many treatments are currently available, unmet need exists for new testosterone (T) replacement therapies that are simple to administer and use, are safe, and mimic physiologic T levels.

AIM: The study aim was to determine the pharmacokinetics (PK), safety, and tolerability of T enanthate (TE) administered via a novel single-use autoinjector system, which was designed to eject high-viscosity solutions from a prefilled syringe fitted with a five-eighths-inch 27-gauge needle.

METHODS: Thirty-nine men with hypogonadism entered this dose-finding, open-label, parallel-group study. Patients were washed out of their topical T regimens and randomized to receive 50 or 100 mg of subcutaneous (SC) TE weekly. The reference group were patients with hypogonadism who were maintained on standard 200-mg intramuscular (IM) TE.

MAIN OUTCOME MEASURE: The primary outcome measure was the PK profile of SC TE, analyzed in reference to T levels used by the Food and Drug Administration to approve T products. Secondary outcome measures were safety and tolerability assessments.

RESULTS: Both doses of SC TE achieved normal average concentrations of serum T within a 168-h dosing interval after injection. Concentration ranges were similar at all time points following 50-mg SC TE injections and following the third injection in the 100-mg arm. Mean steady-state T concentration at week 6 was 422.4 and 895.5 ng/dL for the 50- and 100-mg SC TE arms, respectively. SC TE demonstrated PK dose proportionality. SC TE restored normal serum T with low variation relative to 200-mg IM without clinically significant adverse events.

CONCLUSIONS: Administration of TE via this novel injection system restored T levels to normal range in men with hypogonadism. SC TE dosed weekly demonstrated steady, dose-proportional measures of exposure and was well-tolerated. Kaminetsky J, Jaffe JS, Swerdloff RS. Pharmacokinetic profile of subcutaneous testosterone enanthate delivered via a novel, prefilled single-use autoinjector: A phase II study. Sex Med 2015;3:263-273.

Keywords: Autoinjector; Clinical Trial; Hypogonadism; Male; Phase II; Subcutaneous Injection; Testosterone; Viscosity

References

  1. Diabetes Care. 2011 Apr;34(4):828-37 - PubMed
  2. Ther Clin Risk Manag. 2008 Feb;4(1):269-86 - PubMed
  3. Endocr Pract. 2002 Nov-Dec;8(6):440-56 - PubMed
  4. Ann Pharmacother. 2014 Jul 2;48(9):1138-1144 - PubMed
  5. J Androl. 2012 Mar-Apr;33(2):190-201 - PubMed
  6. Hum Reprod. 2009 Feb;24(2):425-8 - PubMed
  7. JAMA Intern Med. 2013 Aug 12;173(15):1465-6 - PubMed
  8. PLoS One. 2014 Jan 29;9(1):e85805 - PubMed
  9. J Clin Endocrinol Metab. 2007 Nov;92(11):4241-7 - PubMed
  10. Saudi Med J. 2006 Dec;27(12):1843-6 - PubMed
  11. Expert Opin Drug Deliv. 2008 Apr;5(4):471-81 - PubMed
  12. Aging Male. 2008 Dec;11(4):171-8 - PubMed
  13. J Clin Endocrinol Metab. 2004 Dec;89(12):5920-6 - PubMed
  14. Clin Interv Aging. 2007;2(4):577-90 - PubMed
  15. J Androl. 2010 Sep-Oct;31(5):457-65 - PubMed
  16. Eur J Endocrinol. 1995 Apr;132(4):514-9 - PubMed
  17. J Sex Med. 2014 Feb;11(2):553-62 - PubMed
  18. Asian J Androl. 2010 Mar;12(2):227-33 - PubMed
  19. JAMA. 2013 Nov 6;310(17):1829-36 - PubMed
  20. J Clin Endocrinol Metab. 1999 Oct;84(10):3469-78 - PubMed
  21. Heart. 2010 Nov;96(22):1821-5 - PubMed
  22. J Clin Rheumatol. 2014 Aug;20(5):256-60 - PubMed
  23. J Clin Endocrinol Metab. 2010 Jun;95(6):2536-59 - PubMed
  24. Hum Reprod. 1995 Apr;10(4):862-5 - PubMed
  25. Int J Endocrinol. 2012;2012:625434 - PubMed
  26. Int J Clin Pract. 2014 Oct;68(10):1257-63 - PubMed
  27. J Sex Med. 2013 Sep;10(9):2326-33 - PubMed
  28. J Diabetes Sci Technol. 2007 Sep;1(5):725-9 - PubMed
  29. LGBT Health. 2014 Sep;1(3):165-7 - PubMed
  30. J Androl. 2001 Nov-Dec;22(6):1053-60 - PubMed
  31. Clin Endocrinol (Oxf). 1999 Jan;50(1):57-62 - PubMed
  32. Arch Intern Med. 2006 Aug 14-28;166(15):1660-5 - PubMed

Publication Types